Yantai Dongcheng Pharmaceutical GroupLtd Inkomsten in het verleden
Verleden criteriumcontroles 1/6
Yantai Dongcheng Pharmaceutical GroupLtd's earnings have been declining at an average annual rate of -7%, while the Biotechs industry saw earnings growing at 5.9% annually. Revenues have been declining at an average rate of 0.1% per year. Yantai Dongcheng Pharmaceutical GroupLtd's return on equity is 1.2%, and it has net margins of 3.2%.
Belangrijke informatie
-7.0%
Groei van de winst
-7.5%
Groei van de winst per aandeel
Biotechs Groei van de industrie | 11.3% |
Inkomstengroei | -0.1% |
Rendement op eigen vermogen | 1.2% |
Nettomarge | 3.2% |
Laatste winstupdate | 30 Sep 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Yantai Dongcheng Pharmaceutical GroupLtd (SZSE:002675) Has A Pretty Healthy Balance Sheet
Aug 23Yantai Dongcheng Pharmaceutical Group Co.,Ltd.'s (SZSE:002675) Business Is Yet to Catch Up With Its Share Price
Jul 12News Flash: 7 Analysts Think Yantai Dongcheng Pharmaceutical Group Co.,Ltd. (SZSE:002675) Earnings Are Under Threat
May 06Yantai Dongcheng Pharmaceutical GroupLtd's (SZSE:002675) Problems Go Beyond Weak Profit
May 05Is Yantai Dongcheng Pharmaceutical GroupLtd (SZSE:002675) A Risky Investment?
Mar 15Yantai Dongcheng Pharmaceutical Group Co.,Ltd.'s (SZSE:002675) P/E Is On The Mark
Feb 27Opbrengsten en kosten
Hoe Yantai Dongcheng Pharmaceutical GroupLtd geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
---|---|---|---|---|
30 Sep 24 | 2,853 | 91 | 696 | 226 |
30 Jun 24 | 2,911 | 137 | 679 | 204 |
31 Mar 24 | 3,072 | 224 | 689 | 195 |
31 Dec 23 | 3,276 | 210 | 749 | 197 |
30 Sep 23 | 3,427 | 263 | 796 | 189 |
30 Jun 23 | 3,603 | 323 | 849 | 180 |
31 Mar 23 | 3,554 | 302 | 847 | 174 |
01 Jan 23 | 3,583 | 307 | 788 | 164 |
30 Sep 22 | 3,858 | 220 | 804 | 145 |
30 Jun 22 | 3,851 | 165 | 802 | 146 |
31 Mar 22 | 3,902 | 140 | 791 | 144 |
01 Jan 22 | 3,912 | 152 | 804 | 138 |
30 Sep 21 | 3,637 | 341 | 759 | 129 |
30 Jun 21 | 3,599 | 353 | 860 | 117 |
31 Mar 21 | 3,596 | 411 | 895 | 122 |
31 Dec 20 | 3,419 | 418 | 898 | 109 |
30 Sep 20 | 3,395 | 214 | 1,010 | 104 |
30 Jun 20 | 3,312 | 196 | 991 | 103 |
31 Mar 20 | 3,172 | 164 | 1,022 | 92 |
31 Dec 19 | 2,993 | 155 | 1,001 | 89 |
30 Sep 19 | 2,877 | 366 | 976 | 62 |
30 Jun 19 | 2,709 | 347 | 884 | 74 |
31 Mar 19 | 2,467 | 302 | 793 | 72 |
31 Dec 18 | 2,333 | 280 | 732 | 65 |
30 Sep 18 | 2,098 | 228 | 586 | 99 |
30 Jun 18 | 1,842 | 212 | 515 | 68 |
31 Mar 18 | 1,679 | 185 | 478 | 48 |
31 Dec 17 | 1,596 | 173 | 449 | 40 |
30 Sep 17 | 1,511 | 172 | 471 | 0 |
30 Jun 17 | 1,377 | 149 | 407 | 0 |
31 Mar 17 | 1,245 | 145 | 351 | 0 |
31 Dec 16 | 1,158 | 131 | 311 | 0 |
30 Sep 16 | 1,014 | 119 | 247 | 0 |
30 Jun 16 | 903 | 95 | 223 | 0 |
31 Mar 16 | 852 | 83 | 194 | 0 |
31 Dec 15 | 795 | 90 | 175 | 0 |
30 Sep 15 | 725 | 94 | 122 | 0 |
30 Jun 15 | 724 | 99 | 119 | 0 |
31 Mar 15 | 727 | 103 | 123 | 0 |
31 Dec 14 | 751 | 104 | 119 | 0 |
30 Sep 14 | 786 | 99 | 124 | 0 |
30 Jun 14 | 783 | 96 | 105 | 0 |
31 Mar 14 | 782 | 91 | 89 | 0 |
31 Dec 13 | 775 | 101 | 77 | 0 |
Kwaliteitswinsten: 002675 has high quality earnings.
Groeiende winstmarge: 002675's current net profit margins (3.2%) are lower than last year (7.7%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: 002675's earnings have declined by 7% per year over the past 5 years.
Versnelling van de groei: 002675's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Winst versus industrie: 002675 had negative earnings growth (-65.5%) over the past year, making it difficult to compare to the Biotechs industry average (0.08%).
Rendement op eigen vermogen
Hoge ROE: 002675's Return on Equity (1.2%) is considered low.